Jake R. Morgan, PhD
Research Assistant Professor
Boston University School of Public Health
Dept of Health Law, Policy & Management

PhD, Boston University
MS, Montana State University



Jake Morgan, PhD, is a health services researcher specializing in using real-world data to inform evidence-based policy, update clinical guidelines, and improve patient access to and quality of care.

His work is focused on the opioid overdose epidemic and how to best support patients by promoting access and retention to medications for opioid use disorder. His work on the comparative effectiveness of medications for opioid use disorder has been cited in a call for research by the director of the National Institute on Drug Abuse Nora Volkow and he has a history of collaboration with Massachusetts Department of Public Health to evaluate and inform addiction treatment services. His work has consistently reinforced the importance of patient choice when it comes to treatment for opioid use disorder and has documented the effects of policies that usurp this choice through onerous requirements for treatment, restricting access to vulnerable populations such as individuals who are incarcerated, and cost-sharing schemes that disincentivize treatment. As an applied health economist with extensive experience in statistical, econometric, and simulation modeling approaches, Dr. Morgan frequently works alongside clinical researchers to highlight (and cost) the best treatment interventions for patients. He is currently involved with the Health Economics core of the The HEALing Communities Study; the Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND) study; the Researching Effective Strategies to Prevent Opioid Death (RESPOND) simulation model, and; The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV trial.

Dr. Morgan works closely with The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) as a member of the Population Data and Modeling Core and is the primary representative for Boston University School of Public Health. The Center’s mission is to develop and disseminate health economic research on healthcare utilization, health outcomes, and health-related behaviors to inform policy to improve care for individuals with substance use disorder, HIV, and HCV. To that end, CHERISH offers resources and consultations to support this type of research for trainees and investigators at any stage. Please see https://cherishresearch.org/ or contact Dr. Morgan to learn more.


IMPROVING NALOXONE ACCESS AND ITS EFFECTS ON DRUG ABUSE AND OVERDOSES
02/25/2019 - 08/31/2023 (Subcontract PI)
RAND Corporation HHS CDC
5R01CE002999-02

Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Evaluating Intervention Outcomes for Individuals, Systems, and Communities
07/15/2020 - 04/30/2023 (Subcontract PI)
Weill Medical College of Cornell University NIH NIDA
5P30DA040500-08

Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)
05/15/2019 - 02/28/2023 (Subcontract PI)
Weill Medical College of Cornell NIH NIDA
5U01DA047408-03

The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV Trial
01/01/2019 - 12/31/2022 (Subcontract PI)
Denver Health Medical Center NIH NIDA
5R01DA042982-05

Expanding FDA's Opioids Systems Model to Enable Economic Evaluations and Outcome Analyses of National Opioid Policies
09/01/2020 - 08/31/2022 (Subcontract PI)
The General Hospital Corporation d/b/a Massachusetts General Hospital HHS FDA
1U01FD007064-01

Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorder
05/01/2021 - 04/30/2022 (Subcontract PI)
Weill Medical College of Cornell NIH NIDA
3P30DA040500-07S1

Impact of health insurance type and transitions on treatment for opioid use disorder
04/01/2019 - 03/31/2022 (Subcontract PI)
Boston Medical Center Corporation Robert Wood Johnson


Researching Effective Strategies to Prevent Opioid Death (RESPOND)
04/01/2019 - 03/31/2022 (Subcontract PI)
Boston Medical Center Corporation NIH NIDA
5R01DA046527-04

CFAR Developmental Award: Assessing Trends in HIV PrEP Uptake Among Persons Who Inject Drugs
07/01/2020 - 12/31/2021 (Subcontract PI)
Boston Medical Center Corporation NIH NIAID
5P30AI042853-22

Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (CHERISH Supplement)
05/01/2019 - 07/15/2020 (Subcontract PI)
Weill Medical College of Cornell NIH NIDA
3P30DA040500-05S1

Showing 10 of 12 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Morgan JR, Murphy SM, Assoumou SA, Linas BP. Estimating Absenteeism Related to Nonalcohol Substance Use in a US National Cohort of Full-Time Employees. J Occup Environ Med. 2022 Nov 01; 64(11):899-904.View Related Profiles. PMID: 35901222; PMCID: PMC9637773; DOI: 10.1097/JOM.0000000000002612;
     
  2. Streed CG, Morgan JR, Gai MJ, Larochelle MR, Paasche-Orlow MK, Taylor JL. Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use. JAMA Netw Open. 2022 Jul 01; 5(7):e2221346.View Related Profiles. PMID: 35819784; PMCID: PMC9277489; DOI: 10.1001/jamanetworkopen.2022.21346;
     
  3. Morgan JR, LaRochelle MR. Commentary on Karnik et al.: Harmonization now-the need for consistent, validated measures to identify opioid use disorder in observational data. Addiction. 2022 Sep; 117(9):2448-2449.View Related Profiles. PMID: 35762525
     
  4. Epstein RL, Wang J, White LF, Kapadia SN, Morgan JR, Bao Y, Linas BP. Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured. Am J Prev Med. 2022 Sep; 63(3):e87-e98.View Related Profiles. PMID: 35725599
     
  5. Nguemeni Tiako MJ, Meinhofer A, Friedman A, South EC, Epstein RL, Meisel ZF, Morgan JR. Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorder. Am J Obstet Gynecol. 2022 Sep; 227(3):544-546.e1.View Related Profiles. PMID: 35613648; PMCID: PMC9420821; DOI: 10.1016/j.ajog.2022.05.041;
     
  6. Tabatabaeepour N, Morgan JR, Jalali A, Kapadia SN, Meinhofer A. Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder. J Subst Abuse Treat. 2022 Sep; 140:108800. PMID: 35577664; PMCID: PMC9357143; DOI: 10.1016/j.jsat.2022.108800;
     
  7. Haukoos JS, Rowan SE, Galbraith JW, Rothman RE, Hsieh YH, Hopkins E, Houk RA, Toerper MF, Kamis KF, Morgan JR, Linas BP, Al-Tayyib AA, Gardner EM, Lyons MS, Sabel AL, White DAE, Wyles DL. The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments. Trials. 2022 Apr 25; 23(1):354.View Related Profiles. PMID: 35468807; PMCID: PMC9036509; DOI: 10.1186/s13063-022-06265-1;
     
  8. Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022 Sep; 117(9):2450-2461.View Related Profiles. PMID: 35315162; PMCID: PMC9377514; DOI: 10.1111/add.15879;
     
  9. Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, Tsertsvadze T, Kamkamidze G, Alkhazashvili M, Morgan T, Belperio P, Backus L, Doss W, Esmat G, Hassany M, Elsharkawy A, Elakel W, Mehrez M, Foster GR, Wose Kinge C, Chew KW, Chasela CS, Sanne IM, Thanung YM, Loarec A, Aslam K, Balkan S, Easterbrook PJ, Linas BP. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. J Viral Hepat. 2022 Jun; 29(6):474-486.View Related Profiles. PMID: 35278339; PMCID: PMC9248016; DOI: 10.1111/jvh.13672;
     
  10. Morgan JR, Quinn EK, Chaisson CE, Ciemins E, Stempniewicz N, White LF, Linas BP, Walley AY, LaRochelle MR. Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. Med Care. 2022 03 01; 60(3):256-263.View Related Profiles. PMID: 35026792; PMCID: PMC8852217; DOI: 10.1097/MLR.0000000000001689;
     
Showing 10 of 51 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 51 publications over 9 distinct years, with a maximum of 10 publications in 2021 and 2022

YearPublications
20141
20156
20164
20173
20185
20196
20206
202110
202210

2016 Patient-Centered Outcomes Research Institute (PCORI): Trainee Scholarship
2015 Lee Lusted Prize winner
Contact for Mentoring:
Morgan's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department